默沙东与 Kelun-Biotech 的 sac-TMT 在晚期子宫内膜癌 III 期研究中将死亡风险降低三分之一
STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
默沙东与 Kelun-Biotech 的靶向化疗药 sac-TMT(sacituzumab tirumotecan)在晚期子宫内膜癌随机 III 期研究中将死亡风险降低三分之一,结果于周一在马德里公布。
该药已在中国获批,默沙东正以 18 项全球 III 期研究推进海外申报,本篇给出其中一项关键结果。
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
MADRID — A type of targeted chemotherapy developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer, a common gynecological cancer, according to randomized Phase 3 study results presented Monday.
The drug, called sacituzumab tirumotecan, or sac-TMT, has already shown survival-extending benefits for patients across multiple cancer types in studies conducted by Kelun in China, where it’s approved.
Merck is conducting 18 global Phase 3 studies of sac-TMT, including 10 studies in women’s cancers, to support approvals in the U.S., Europe, and elsewhere outside China. The drug plays a crucial role in Merck’s efforts to replace revenue that will be lost when Keytruda, its blockbuster immunotherapy, loses patent protection in 2028.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com